政策、守則及標準
行為準則 (只提供英文版本)
GSK行為準則
- Our Code of Conduct
- Code of Practice for Promotion and Scientific Engagement (prescription medicines)
反貪腐計劃 (ABAC)
反貪腐計劃是GSK為防止賄賂及貪汚而推行的措施。計劃包括ABAC手冊，以協助公司內外各方了解貪汚風險，以及認識主動打擊貪汚(包括懷疑貪汚)的個人責任。
反貪腐計劃第三方指引
我們向所有與GSK有關連的第三方提供指引，讓他們認識我們的反貪腐政策，以及我們對其作為公司業務伙伴的期望。
公共政策 (只提供英文版本)
GSK普及性與發展中國家
- Developing world vaccine production technology transfer
- IP and access to medicines in developing countries
- Technology transfer, capacity building and developing countries
- Non-communicable diseases and the developing world
- The post 2015 development agenda
- Universal healthcare coverage
- Civil society organisations and vaccine procurement
- Working together for the health of mothers and children
GSK與科研
- Clinical trials in the developing world
- Incentivising antibacterial R&D
- Cloning technologies and stem cell research
- The convention on biological diversity
- Disclosure of clinical trial information
- The care, welfare and treatment of animals
- The role of transgenic animals in biomedical research
- Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines
GSK與知識產權
- Incremental innovation
- Compulsory licences
- Evergreening
- Proposals for a disclosure in patent applications
- Regulatory data protection
GSK與環境
- Hazardous chemical management
- Genetically modified micro-organisms and Environment, Health and Safety (EHS)
- GSK and REACH
- Nanotechnology
- Ozone depletion and metered-dose inhalers for asthma
- Pharmaceuticals in environment
- The impact of climate change on health
- Use of ozone depleting substances in ancillary plant and equipment
- GSK and water stewardship
GSK與公共衛生
- Counterfeiting of healthcare products
- Pharmacovigilance
- Paediatric medicines
- Tiered pricing & vaccines
- Pandemic preparedness
- Information to patients
GSK與其他議題
其他報告 (只提供英文版本)
GlaxoSmithKline plc － 專門披露報告
- GlaxoSmithKline plc - 2015 Form SD Conflict Minerals Disclosure
- GlaxoSmithKline plc - 2014 Form SD Conflict Minerals Disclosure
- GlaxoSmithKline plc - 2013 Form SD Conflict Minerals Disclosure
GlaxoSmithKline Capital plc –歐元中期票據計劃
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2015
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2014
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document 2013
- GlaxoSmithKline Euro Medium Term Note Programme – Registration Document
- GlaxoSmithKline Euro Medium Term Note Programme – Prospectus Document
- GlaxoSmithKline Euro Medium Term Note Programme - Supplementary Prospectus Document
GlaxoSmithKline Capital plc –年度報告
- 2015 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2014 Annual Report GlaxoSmithKline Capital plc
- 2014 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2013 Annual Report GlaxoSmithKline Capital plc
- 2013 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2012 Annual Report GlaxoSmithKline Capital plc
- 2012 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2011 Annual Report GlaxoSmithKline Capital plc
- 2011 Half Year Results and Interim Management Report GlaxoSmithKline Capital plc
- 2010 Annual Report GlaxoSmithKline Capital plc
- 2009 Annual Report GlaxoSmithKline Capital plc
- 2008 Annual Report GlaxoSmithKline Capital plc